海外临床试验导航

黑色素瘤

帮助用户按转移性、BRAF、NRAS、KIT、免疫治疗、靶向治疗等方向检索海外公开临床试验。

中文医学标准名: 黑色素瘤
英文医学标准名: Melanoma
试验数据最后同步: 2026-07-10

Synced trials

当前同步到的治疗类试验

以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。

最后同步日期：2026-07-10 · 当前显示 156 条

招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。

正在招募 Phase 2 药物

clinicaltrials.gov NCT07276386

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

适用疾病: Metastatic Uveal Melanoma
干预: Melphalan/HDS (Percutaneous Hepatic Perfusion)，Tebentafusp
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT05428007

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

适用疾病: Melanoma；Unresectable Melanoma
干预: Sarilumab，Ipilimumab Injection，Nivolumab/Relatlimab
地点: United States
申办方: NYU Langone Health

正在招募 Phase 2 药物

clinicaltrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT04771520

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Avapritinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT05076760

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05909618

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

适用疾病: Advanced Glioblastoma；Metastatic Melanoma in the Central Nervous System；MGMT-Unmethylated Glioblastoma
干预: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]，Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
地点: Israel
申办方: Sheba Medical Center

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT05498792

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

适用疾病: Locally Advanced or Metastatic Melanoma
干预: CBL0137，Ipilimumab，Nivolumab
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 3 药物

clinicaltrials.gov NCT07221734

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

适用疾病: Advanced (Unresectable or Metastatic) Melanoma
干预: MB11 (Proposed Nivolumab Biosimilar)，EU-Opdivo®，US- sourced Opdivo®
地点: Portugal，Ukraine
申办方: mAbxience Research S.L.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05877430

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

适用疾病: NSCLC；HNSCC；Melanoma
干预: CJRB-101，Pembrolizumab injection
地点: United States，South Korea
申办方: CJ Bioscience, Inc.

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT05522660

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

适用疾病: Non-Small Cell Lung Cancer；Melanoma
干预: Stereotactic radiosurgery，Immune checkpoint inhibitor
地点: Italy，Netherlands，Spain，Switzerland 等 1 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410494

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

适用疾病: Cancer；Breast Cancer；Non-Small Cell Lung Cancer (NSCLC)
干预: EB-SELECT Single-Target CAR-NK Cells，Dual-Target Antigen-Selected CAR-NK
地点: China
申办方: Essen Biotech

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06626516

Tebentafusp-tebn With LDT in Metastatic UM

适用疾病: Metastatic Uveal Melanoma
干预: Tebentafusp-Tebn，GM-CSF (Sargramostim)，BCNU
地点: United States
申办方: Thomas Jefferson University

即将招募 Phase 1 药物

clinicaltrials.gov NCT07476326

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

适用疾病: Melanoma
干预: Bmab1700，Opdivo
地点: Georgia，Romania，Serbia，South Africa 等 2 个
申办方: Biocon Biologics UK PLC

即将招募 Phase 2 生物制剂手术/操作

clinicaltrials.gov NCT07576725

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Nivolumab
地点: Uganda
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1 生物制剂药物其他

clinicaltrials.gov NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

适用疾病: Metastatic Malignant Solid Neoplasm；Metastatic Melanoma；Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Anusha Kalbasi

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06727630

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

适用疾病: Melanoma
干预: PRJ1-3024
地点: China
申办方: Zhuhai Yufan Biotechnologies Co., Ltd

正在招募 Phase 3 药物

clinicaltrials.gov NCT02821013

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

适用疾病: Unresectable/Metastatic Melanoma
干预: Intermittent PD-1 inhibitor therapy，Continuous PD-1 inhibitor therapy
地点: Australia，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1 药物

clinicaltrials.gov NCT07027488

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

适用疾病: Advanced Melanoma and Normal or Impaired；Advanced Melanoma
干预: AB821
地点: United States
申办方: Yale University

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT05859074

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

适用疾病: Cutaneous Squamous Cell Carcinoma；SCC - Squamous Cell Carcinoma；Basal Cell Carcinoma
干预: MQ719，Pembrolizumab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募阶段未标明放疗

clinicaltrials.gov NCT04793737

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

适用疾病: Metastatic Melanoma
干预: Precision Radiation (SBRT)
地点: Sweden
申办方: Karolinska University Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07237594

IL-17 Blockade to Decrease irAEs (REPLAY)

适用疾病: Metastatic Melanoma
干预: Secukinumab Injection
地点: United States
申办方: Duke University

正在招募 Phase 1 药物

clinicaltrials.gov NCT05746897

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

适用疾病: Ovarian Cancer；Melanoma；Triple Negative Breast Cancer
干预: NM1F Injection，Pembrolizumab injection
地点: United States
申办方: Hefei TG ImmunoPharma Co., Ltd.

正在招募 Phase 1, Phase 2 器械药物

clinicaltrials.gov NCT07281924

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

适用疾病: Metastatic Melanoma；Liver Metastases
干预: Nivolumab and Relatlimab，Melphalan
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06683755

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

适用疾病: Melanoma
干预: Nivolumab，Relatlimab，Ipilimumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06284590

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

适用疾病: Melanoma Stage III；Melanoma Stage IV
干预: L19IL2，L19TNF，L19IL2/L19TNF，KEYTRUDA®
地点: United States
申办方: Philogen S.p.A.

正在招募 Phase 1 药物

clinicaltrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

适用疾病: Tumor Skin；Metastatic Melanoma；Melanoma
干预: OBX-115
地点: United States，Australia
申办方: Obsidian Therapeutics, Inc.

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT02621021

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

适用疾病: Melanoma
干预: young TIL，Pembrolizumab，Aldesleukin，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

clinicaltrials.gov NCT04562129

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

适用疾病: Melanoma Stage III；Melanoma Stage IV；Inoperable Disease
干预: Interleukin-2，Ipilimumab，Nivolumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT06545682

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

适用疾病: Melanoma (Skin Cancer)；Breast Cancer；Brain Metastasases
干预: Alpelisib + Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂联合产品

clinicaltrials.gov NCT04370587

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

适用疾病: Solid Tumor；Melanoma；HNSCC
干预: T3011，T3011 + pembrolizumab
地点: United States，Australia
申办方: ImmVira Pharma Co. Ltd

正在招募阶段未标明放疗

clinicaltrials.gov NCT07112170

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

适用疾病: Metastatic Melanoma；OligoProgressive Metastatic Disease
干预: Stereotactic Body Radiation Therapy (SBRT)
地点: Canada
申办方: University Health Network, Toronto

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06305962

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

适用疾病: PDL1 Gene Mutation；Non Small Cell Lung Cancer；Small Cell Lung Cancer ( SCLC )
干预: 177Lu-RAD204
地点: Australia
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT05607095

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

适用疾病: Uveal Melanoma；Melanoma；Metastatic Uveal Melanoma
干预: Lifileucel (LN-144/LN-145)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 2 药物

clinicaltrials.gov NCT07340619

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

适用疾病: Metastatic (Stage IV) Melanoma
干预: prifetrastat monotherapy for 15 days then combination with fulvestrant，prifetrastat in combination with fulvestrant
地点: France
申办方: UNICANCER

正在招募 Phase 4 器械药物

clinicaltrials.gov NCT07504796

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

适用疾病: Metastatic Melanoma；Advanced Melanoma
干预: Nivolumab，Relatlimab，Ipilimumab，Signatera genome MRD assay
地点: United States
申办方: NYU Langone Health

正在招募 Phase 1 生物制剂药物手术/操作

clinicaltrials.gov NCT05098210

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8；Locally Advanced Cutaneous Melanoma
干预: Neoantigen Peptide Vaccine，Nivolumab，Poly ICLC，Echocardiography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 生物制剂

clinicaltrials.gov NCT06797297

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

适用疾病: Melanoma
干预: IBI363，Pembrolizumab
地点: China
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT03563729

Melanoma Metastasized to the Brain and Steroids

适用疾病: Malignant Melanoma
干预: Pembrolizumab Injection [Keytruda]，Ipilimumab Injection [Yervoy]，Nivolumab Injection [Opdivo]，Encorafenib
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06425926

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

适用疾病: Melanoma Stage IV；Solid Tumor
干预: GIM-531，Anti-PD-1 monoclonal antibody
地点: United States
申办方: Georgiamune Inc

正在招募 Phase 2 药物

clinicaltrials.gov NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Tumor；Melanoma；Head and Neck Cancer
干预: HER3-DXd
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT03685890

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

适用疾病: Melanoma；In-Transit Metastasis
干预: Nivolumab，Isolated limb perfusion (ILP)
地点: Netherlands，Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT06767306

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

适用疾病: Melanoma Metastatic
干预: Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy，Immunotherapy alone
地点: Australia，Canada
申办方: Melanoma Institute Australia

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07136181

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

适用疾病: Metastatic Uveal Melanoma；Uveal Melanoma, Metastatic；Uveal Melanoma, Recurrent
干预: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
地点: United States
申办方: Novelwise Pharmaceutical Corporation

正在招募 Phase 2 药物

clinicaltrials.gov NCT06070012

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

适用疾病: Uveal Melanoma
干预: Tebentafusp
地点: United States
申办方: Diwakar Davar

即将招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT06708455

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

适用疾病: Malignant Melanoma With Metastasis；Malignant Melanoma；Malignant Melanoma Stage IIIc
干预: RAPA-201 Rapamycin Resistant T Cells，Chemotherapy Prior to RAPA-201 Therapy
地点: United States
申办方: Rapa Therapeutics LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07115043

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT05896839

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Ipilimumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06697301

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

适用疾病: Advanced Melanoma
干预: EIK1001，Pembrolizumab (KEYTRUDA® )
地点: United States，Australia，Austria，Belgium 等 20 个
申办方: Eikon Therapeutics

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT05779423

Cryoablation+Ipilimumab+Nivolumab in Melanoma

适用疾病: Metastatic Melanoma；Skin Cancer
干预: Ipilimumab，Nivolumab，Cryoablation
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03947385

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

适用疾病: Metastatic Uveal Melanoma；Cutaneous Melanoma；Colorectal Cancer
干预: IDE196，Binimetinib，Crizotinib
地点: United States，Australia，Canada
申办方: IDEAYA Biosciences

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06413680

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

适用疾病: Melanoma；Clear-Cell Renal-Cell Carcinoma (ccRCC)；Advanced Solid Tumors
干预: REGN10597，Cemiplimab
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物

clinicaltrials.gov NCT06121180

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

适用疾病: Metastatic Uveal Melanoma
干预: ZIV-Aflibercept，Cemiplimab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT06216938

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

适用疾病: Melanoma
干预: Vusolimogene oderparepvec (RP1)
地点: United States
申办方: Yana Najjar

正在招募 Phase 2 药物

clinicaltrials.gov NCT06295159

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

适用疾病: Melanoma Stage III；Melanoma Stage IV；Advanced Melanoma
干预: Nivolumab，Nivolumab + Relatlimab，Ipilimumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募阶段未标明药物

clinicaltrials.gov NCT05652673

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

适用疾病: Melanoma Stage IV；Melanoma Stage III；Immunotherapy
干预: nivolumab
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06209580

AMT-253 in Patients With Advanced Solid Tumours

适用疾病: Malignant Melanoma；Advanced Solid Tumors
干预: AMT-253 for injection
地点: China
申办方: Multitude Therapeutics Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07063875

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

适用疾病: Uveal Melanoma；Metastatic Uveal Melanoma；Metastatic Uveal Melanoma in the Liver
干预: Aldesleukin
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 1 药物

clinicaltrials.gov NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06805825

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

适用疾病: Gastrointestinal Stromal Tumors；Small-cell Lung Cancer；Adenoid Cystic Carcinoma
干预: NN3201
地点: United States
申办方: Novelty Nobility, Inc.

正在招募 Phase 3 生物制剂

clinicaltrials.gov NCT05727904

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

适用疾病: Metastatic Melanoma；Unresectable Melanoma；Melanoma
干预: Lifileucel plus Pembrolizumab，Pembrolizumab with Optional Crossover Period
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Iovance Biotherapeutics, Inc.

即将招募 Phase 1 药物

clinicaltrials.gov NCT07183852

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

适用疾病: Metastatic Uveal Melanoma；Metastatic Cutaneous Melanoma
干预: Autologous Tumor Infiltrating Lymphocytes (TIL)，Melphalan，Interleukin-2
地点: 未列出
申办方: Vastra Gotaland Region

正在招募 Phase 2, Phase 3 生物制剂

clinicaltrials.gov NCT06581406

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

适用疾病: Metastatic Uveal Melanoma
干预: RP2，Ipilimumab，Nivolumab
地点: United States，Australia，United Kingdom
申办方: Replimune, Inc.

即将招募 Phase 1 药物

clinicaltrials.gov NCT05903937

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

适用疾病: Uveal Melanoma；Metastatic Cutaneous Melanoma
干预: Autologous Tumor Infiltrating Lymphocytes，Melphalan，Interleukin-2
地点: 未列出
申办方: Vastra Gotaland Region

正在招募 Phase 1 诊断检测药物

clinicaltrials.gov NCT07076550

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

适用疾病: Melanoma Metastatic；Uveal Melanoma, Metastatic；Mucosal Melanoma
干预: [225Ac]Ac-A9-3408，[68Ga]Ga-A9T-3202
地点: Australia
申办方: Alpha-9 Oncology USA Inc.

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06889610

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

适用疾病: Triple Negative Breast Cancer Metastatic；Melanoma Metastatic；Colorectal Cancer Metastatic
干预: MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer，MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer，MTT(Multimodal Tumor Thermal Therapy System)- Melanoma
地点: China
申办方: Fudan University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06066138

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

适用疾病: Locally Advanced Alveolar Soft Part Sarcoma；Metastatic Alveolar Soft Part Sarcoma；Locally Advanced Non Small Cell Lung Cancer
干预: Atezolizumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 手术/操作放疗

clinicaltrials.gov NCT06500455

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Digestive System Carcinoma
干预: Computed Tomography，Fractionated Stereotactic Radiation Therapy，Magnetic Resonance Imaging，Stereotactic Radiosurgery
地点: United States，Canada，Hong Kong，Ireland
申办方: NRG Oncology

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT05269381

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

clinicaltrials.gov NCT05968690

Naltrexone and Propranolol Combined With Immunotherapy

适用疾病: Advanced Melanoma
干预: Propranolol，Naltrexone
地点: United States
申办方: Sarah Weiss

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT07130032

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

适用疾病: Metastatic Non-small Cell Lung Cancer (NSCLC)；Metastatic Cutaneous Melanoma
干预: reICB regimen (NSCLC)，reICB regimen (melanoma)
地点: Russia
申办方: EuroCityClinic LLC

正在招募 Phase 2 药物

clinicaltrials.gov NCT05913388

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

适用疾病: Metastatic Melanoma；Head and Neck Squamous Cell Carcinoma
干预: GB1211，Pembrolizumab，Placebo
地点: United States
申办方: Providence Health & Services

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06362369

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

适用疾病: Advanced Cancer；Advanced Solid Tumor；Melanoma
干预: Alintegimod，Ipilimumab，Nivolumab
地点: United States
申办方: 7 Hills Pharma, LLC

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT04741997

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

适用疾病: Melanoma Stage III；Melanoma Stage IV；BRAF V600 Mutation
干预: Encorafenib Pill，Binimetinib Pill，Nivolumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物其他放疗

clinicaltrials.gov NCT03340129

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

适用疾病: Melanoma Stage Iv
干预: Ipilimumab，Nivolumab，Stereotactic Radiotherapy，Salvage therapy
地点: Australia，Norway
申办方: Melanoma Institute Australia

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05655312

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

适用疾病: Recurrent Melanoma (Skin)；Metastatic Melanoma；Melanoma Stage IV
干预: [203Pb]VMT01，[212Pb]VMT01，Nivolumab
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07627698

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

适用疾病: Unresectable Melanoma；Metastatic Cutaneous Melanoma；Metastatic Uveal Melanoma
干预: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells，Fludarabine，Cyclophosphamide
地点: China
申办方: Beijing Biotech

正在招募 Phase 1 药物

clinicaltrials.gov NCT07376707

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

适用疾病: CRC (Colorectal Cancer)；Melanoma (Skin Cancer)；HCC - Hepatocellular Carcinoma
干预: TGI-5
地点: China
申办方: Hefei TG ImmunoPharma Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

适用疾病: Head and Neck Cancer；Malignant Melanoma；Colorectal Cancer
干预: GM103 (Part A)，GM103 (Part B)，GM103 and Pembrolizumab (Part C)
地点: South Korea
申办方: GeneMedicine Co., Ltd.

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT06204991

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

适用疾病: Melanoma Stage III；Melanoma Stage IV；Melanoma
干预: ADP-TILIL7，Cyclophosphamide，Fludarabine Phosphate，Proleukin
地点: Denmark
申办方: Inge Marie Svane

即将招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT07651618

A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma

适用疾病: Melanoma (Skin Cancer)；Melanoma Metastatic
干预: Tumour Infiltrating Lymphocytes Adoptive Cell Therapy，Cyclophosphamide + Fludarabine Lymphodepletive Conditioning，Aldesleukin
地点: Australia
申办方: East Metropolitan Health Service, Australia

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07339176

Intratumoral N17350 in Advanced Solid Tumors

适用疾病: Neoplasms, Solid Tumor；Breast Neoplasms, Triple-Negative；Squamous Cell Carcinoma of Skin
干预: N17350
地点: Australia
申办方: Onchilles Pharma Inc

即将招募 Phase 4 药物

clinicaltrials.gov NCT07459543

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

适用疾病: Untreated Melanoma；Unresectable Melanoma；Metastatic Melanoma
干预: Nivolumab + Relatlimab
地点: India
申办方: Bristol-Myers Squibb

正在招募阶段未标明药物

clinicaltrials.gov NCT05878977

Biomarkers in Immunotherapy of Melanoma

适用疾病: Metastatic Melanoma；Immune Checkpoints Inhibitors；Gastrointestinal Microbiome (Bacterial and Viral)
干预: Immune checkpoint inhibitor
地点: Slovenia
申办方: Institute of Oncology Ljubljana

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07280832

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

适用疾病: Unresectable Locally Advanced or Metastatic Melanoma
干预: JMT108
地点: China
申办方: Shanghai JMT-Bio Inc.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06783270

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

适用疾病: Melanoma Metastatic
干预: TIL therapy
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT02830724

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

适用疾病: Pancreatic Cancer；Renal Cell Cancer；Breast Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Anti-hCD70 CAR transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

clinicaltrials.gov NCT07448831

A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

适用疾病: Melanoma (Skin Cancer)
干预: Pembrolizumab
地点: Belgium
申办方: Universitair Ziekenhuis Brussel

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT04598009

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

适用疾病: Melanoma Stage III；Melanoma Stage IV
干预: Binimetinib，Imatinib
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT05296564

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

适用疾病: Sarcoma, Synovial；Sarcoma,Soft Tissue；Melanoma Stage IV
干预: CYCLOPHOSPHAMIDE and FLUDARABIN，Cyclophosphamide，HBI 0201-ESO TCRT，Aldesleukin
地点: Israel
申办方: Hadassah Medical Organization

正在招募 Phase 3 药物

clinicaltrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05267626

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

适用疾病: Advanced Solid Tumor；Metastatic Cancer；Cutaneous Melanoma
干预: AU-007，Aldesleukin，Avelumab，Nivolumab
地点: United States，Australia
申办方: Aulos Bioscience, Inc.

正在招募阶段未标明其他手术/操作

clinicaltrials.gov NCT06363591

WoW - Single- vs Two-staged Excisions of Thin Melanoma

适用疾病: Melanoma
干预: Surgery，No Surgery
地点: Sweden
申办方: Vastra Gotaland Region

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07631325

Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma

适用疾病: Unresectable Cutaneous Melanoma
干预: Axelopran，Nivolumab
地点: United States
申办方: John Kirkwood

正在招募 Phase 2 药物

clinicaltrials.gov NCT05155033

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

适用疾病: Metastatic Melanoma；Advanced Locoregional Melanoma；Metastatic Renal Cell Carcinoma
干预: Pembrolizumab，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 药物手术/操作

clinicaltrials.gov NCT07015190

Neoadjuvant Darovasertib in Primary Uveal Melanoma

适用疾病: Uveal Melanoma
干预: Darovasertib，Primary Local Therapy
地点: United States，Australia，Austria，Belgium 等 17 个
申办方: IDEAYA Biosciences

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06359860

A Study of ST-1898 for Unresectable or Metastatic Melanoma

适用疾病: Unresectable or Metastatic Melanoma
干预: ST-1898 tablets
地点: China
申办方: Beijing Scitech-Mq Pharmaceuticals Limited

正在招募 Phase 3 药物

clinicaltrials.gov NCT06246149

Adjuvant Tebentafusp in High Risk Ocular Melanoma

适用疾病: Uveal Melanoma
干预: Tebentafusp
地点: United States，Belgium，France，Germany 等 5 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 2 联合产品药物

clinicaltrials.gov NCT07449754

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

适用疾病: Advanced or Metastatic Melanoma
干预: Belvarafenib，Cobimetinib
地点: South Korea
申办方: Hanmi Pharmaceutical Company Limited

正在招募阶段未标明放疗

clinicaltrials.gov NCT05837767

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

适用疾病: Invasive Ductal Breast Carcinoma；Invasive Ductal Breast Carcinoma Stage IV；Lobular Breast Carcinoma
干预: Palliative radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06627244

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

适用疾病: Metastatic Uveal Melanoma；Metastatic Uveal Melanoma in the Liver
干预: Tebentafusp，TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
地点: United States
申办方: University of Miami

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT05538130

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

适用疾病: Melanoma；Glioma；Thyroid Cancer
干预: PF-07799544，PF-07799933
地点: United States，Australia，Brazil，Canada 等 3 个
申办方: Pfizer

正在招募 Phase 1 药物

clinicaltrials.gov NCT07086105

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

适用疾病: Metastatic Melanoma
干预: Adze1.C
地点: Australia
申办方: Adze Biotechnology Australia Pty Ltd

正在招募 Phase 1 药物

clinicaltrials.gov NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

适用疾病: Solid Tumor, Adult；Microsatellite Stable Colorectal Cancer；Head and Neck Squamous Cell Carcinoma
干预: VET3-TGI，Atezolizumab
地点: United States
申办方: KaliVir Immunotherapeutics

正在招募 Phase 2 药物

clinicaltrials.gov NCT07237100

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

适用疾病: Advanced Unresectable Melanoma；Metastatic Melanoma
干预: Mirdametinib
地点: United States
申办方: Kevin Kim, MD

正在招募 Phase 2 药物

clinicaltrials.gov NCT06319196

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

适用疾病: Cutaneous Melanoma；Melanoma Stage IV；Mucosal Melanoma
干预: Opdualag，Nivolumab
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06090266

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

适用疾病: Cancer；Tumor, Solid；Malignant Neoplasm
干预: OR502，Cemiplimab
地点: United States
申办方: OncoResponse, Inc.

正在招募 Phase 4 药物

clinicaltrials.gov NCT03340506

Dabrafenib and/or Trametinib Rollover Study

适用疾病: Melanoma；Non Small Cell Lung Cancer；Solid Tumor
干预: dabrafenib，trametinib
地点: United States，Argentina，Austria，China 等 8 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

clinicaltrials.gov NCT06022029

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

适用疾病: Triple Negative Breast Cancer；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: ONM-501，Cemiplimab
地点: United States，Australia
申办方: OncoNano Medicine, Inc.

正在招募 Phase 3 药物

clinicaltrials.gov NCT06246916

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

适用疾病: Melanoma
干预: fianlimab，cemiplimab，relatlimab+nivolumab
地点: United States，Canada
申办方: Regeneron Pharmaceuticals

即将招募 Phase 2 药物

clinicaltrials.gov NCT06327698

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

适用疾病: Melanoma
干预: Cadonilimab，anlotinib
地点: 未列出
申办方: Hunan Cancer Hospital

正在招募阶段未标明药物

clinicaltrials.gov NCT07407166

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

适用疾病: Metastatic Melanoma；Melanoma
干预: Immunotherapy
地点: Slovenia
申办方: Institute of Oncology Ljubljana

正在招募 Phase 1 药物

clinicaltrials.gov NCT06332755

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

适用疾病: Non-small Cell Lung Cancer(NSCLC)；Head and Neck Squamous Cell Carcinoma(HNSCC)；Renal Cell Carcinoma(RCC)
干预: Phase 1a: LB-LR1109，Phase 1b: LB-LR1109 and Atezolizumab
地点: United States
申办方: LG Chem

正在招募 Phase 1 生物制剂药物放疗

clinicaltrials.gov NCT06889766

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

适用疾病: Advanced Melanoma；Melanoma Metastatic；Sarcoma
干预: NY-ESO-1 TCR redirected autologous T cell product，Low-dose irradiation，Non-myeloablative lymphodepleting chemotherapy
地点: Switzerland
申办方: Centre Hospitalier Universitaire Vaudois

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT05588453

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

适用疾病: Clinical Stage IV Cutaneous Melanoma AJCC v8；Metastatic Malignant Neoplasm in the Brain；Metastatic Melanoma
干预: Natural Killer Cell Therapy，Temozolomide
地点: United States
申办方: Kari Kendra

正在招募 Phase 1 药物

clinicaltrials.gov NCT07203391

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

适用疾病: Uveal Melanoma, Metastatic
干预: roginolisib
地点: Australia
申办方: St Vincent's Hospital, Sydney

即将招募 Phase 2 器械药物

clinicaltrials.gov NCT07619898

PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure

适用疾病: Colitis；Hepatitis；Melanoma (Skin Cancer)
干预: methoxsalen，Extracorporeal photopheresis (ECP)，Vedolizumab，Infliximab
地点: 未列出
申办方: Therakos LLC

即将招募 Phase 1 药物

clinicaltrials.gov NCT07252661

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

适用疾病: Hepatocellular Carcinoma；Renal Cell Carcinoma；Thyroid Carcinoma, Medullary
干预: ACC-1898
地点: 未列出
申办方: AccSalus Biosciences, Inc.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06946225

ACTengine® IMA203 Combined With mRNA-4203

适用疾病: Cutaneous Melanoma；Synovial Sarcoma
干预: IMA203，mRNA-4203
地点: United States
申办方: Immatics US, Inc.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT03646617

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

适用疾病: Metastatic Melanoma
干预: Hypofractionated Radiation Therapy (HFRT)，Nivolumab，Ipilimumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 3 生物制剂药物

clinicaltrials.gov NCT06743126

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

适用疾病: Melanoma, Cutaneous Malignant
干预: IMA203，nivolumab plus relatlimab，lifileucel，nivolumab
地点: United States，Canada，France，Germany 等 2 个
申办方: Immatics US, Inc.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT05361174

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

适用疾病: Unresectable Melanoma；Metastatic Melanoma；Stage III Non-small Cell Lung Cancer
干预: IOV-4001
地点: United States
申办方: Iovance Biotherapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT05970497

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

适用疾病: Cancer；Melanoma Stage III；Melanoma Stage IV
干预: KB707，Opdualag，KEYTRUDA ®( Pembrolizumab)
地点: United States
申办方: Krystal Biotech, Inc.

正在招募 Phase 4 药物手术/操作

clinicaltrials.gov NCT07405086

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Hepatocellular Carcinoma
干预: Biospecimen Collection，Immune Checkpoint Inhibitor
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT05629546

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

适用疾病: Advanced Melanoma；Metastatic Melanoma
干预: Cytokine-induced memory-like natural killer cells，Relatilmab，Nivolumab
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

clinicaltrials.gov NCT04903119

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

适用疾病: Metastatic Melanoma；BRAF Gene Mutation
干预: Nilotinib 100mg，Nilotinib 200mg，Nilotinib 300mg，Nilotinib 400mg
地点: United States
申办方: Rina Plattner

正在招募 Phase 1 生物制剂手术/操作

clinicaltrials.gov NCT04697576

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

适用疾病: Clinical Stage I Cutaneous Melanoma AJCC v8；Clinical Stage IA Cutaneous Melanoma AJCC v8；Clinical Stage IB Cutaneous Melanoma AJCC v8
干预: Ipilimumab，Nivolumab，Pembrolizumab，Quadrivalent Inactivated Influenza Vaccine
地点: United States
申办方: Carlo Contreras

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

适用疾病: Hepatocellular Carcinoma (HCC)；Metastatic Uveal Melanoma；Renal Cell Carcinoma (RCC)
干预: VMD-102
地点: United States
申办方: VM Discovery, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07057596

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

适用疾病: Mestastatic Uveal Melanoma
干预: Tebentafusp
地点: Germany，Spain
申办方: Grupo Español Multidisciplinar de Melanoma

正在招募 Phase 2 药物

clinicaltrials.gov NCT06771544

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

适用疾病: Melanoma；Melanoma Stage III；Melanoma (Skin)
干预: Pembrolizumab，Cyclophosphamide
地点: United States
申办方: University of California, Irvine

正在招募 Phase 1 药物

clinicaltrials.gov NCT03454035

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

适用疾病: Tumor, Solid；Pancreatic Cancer；Melanoma
干预: Ulixertinib，Palbociclib
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

适用疾病: Cancer；Sarcoma；Leukaemia
干预: EBNK-001 + IL-15 + Pembrolizumab
地点: China
申办方: Essen Biotech

正在招募 Phase 1 药物

clinicaltrials.gov NCT04855435

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

适用疾病: Advanced Solid Tumor；Uveal Melanoma, Metastatic；Cutaneous Melanoma
干预: MBS8(1V270)，MBS8(1V270) and pembrolizumab combination
地点: Denmark，Spain
申办方: MonTa Biosciences ApS

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT04511013

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

适用疾病: Acral Lentiginous Melanoma；Clinical Stage IV Cutaneous Melanoma AJCC v8；Metastatic Cutaneous Melanoma
干预: Binimetinib，Encorafenib，Ipilimumab，Nivolumab
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Cabozantinib S-malate，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05275374

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

适用疾病: Cancer；BRAF V600 Mutation；Melanoma
干预: XP-102，Trametinib
地点: 未列出
申办方: Xynomic Pharmaceuticals, Inc.

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07440290

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

适用疾病: Haematological Malignancy；Malignant Neoplasm；Lymphoproliferative Disorders
干预: Dabrafenib，Trametinib
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 1 药物

clinicaltrials.gov NCT07584226

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

适用疾病: Advanced NRAS-Mutant Melanoma；Advanced NRAS-Mutant Solid Tumors；NRAS Mutation
干预: RLY-8161
地点: United States
申办方: Relay Therapeutics, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07170293

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

适用疾病: Solid Cancers
干预: Tunlametinib
地点: China
申办方: Tianjin Medical University Second Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT06326411

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

适用疾病: Oncology；MEK Mutation；RAF Gene Mutation
干预: NST-628
地点: United States，Australia
申办方: Nested Therapeutics, Inc

正在招募 Phase 3 药物

clinicaltrials.gov NCT06008106

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

适用疾病: Melanoma
干预: tunlametinib，paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
地点: China
申办方: Shanghai Kechow Pharma, Inc.

正在招募 Phase 4 药物

clinicaltrials.gov NCT07445022

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

适用疾病: Melanoma Advanced
干预: tunlametinib
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06961357

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

适用疾病: Melanoma
干预: Cyclophosphamide，Fludarabine，Interleukin-2，TIL Product
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT07501117

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

适用疾病: Uveal Melanoma
干预: Nivolumab & Ipilimumab
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 2 药物

clinicaltrials.gov NCT06932757

Adjuvant Quisinostat in High-Risk Uveal Melanoma

适用疾病: Uveal Melanoma
干预: Quisinostat
地点: United States
申办方: University of Miami

即将招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT07406724

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

适用疾病: Melanoma (Excluding Uveal Melanoma)
干预: Tumor Tissue Sampling，Lymphodepletion Conditioning，Infusion of HS-IT101 Injection，IL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy
地点: 未列出
申办方: Qingdao Sino-Cell Biomedicine Co., Ltd.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT04729543

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

适用疾病: Melanoma；Melanoma, Uveal；Head and Neck Cancer
干预: Adoptive therapy with autologous MC2 TCR T cells
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06414590

Neoadjuvant Tebentafusp for Uveal Melanoma

适用疾病: Locally Advanced Unresectable Uveal Melanoma
干预: Tebentafusp-Tebn
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 3 器械药物

clinicaltrials.gov NCT06519266

PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

适用疾病: Uveal Melanoma；Liver Metastases
干预: PHP，IPI1/NIVO3，IPI3/NIVO1
地点: Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 3 器械药物

clinicaltrials.gov NCT06007690

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

适用疾病: Choroidal Melanoma；Indeterminate Lesions；Uveal Melanoma
干预: Bel-sar，Suprachoroidal Microinjector，Infrared Laser，Sham Infrared Laser
地点: United States，Australia，Austria，Belgium 等 10 个
申办方: Aura Biosciences

每页显示

第 1 页

Subtypes

建议拆分方向

melanomametastatic melanomaBRAF V600NRAS mutationKIT mutationimmune checkpoint inhibitorPD-1CTLA-4uveal melanoma

Keywords

英文搜索关键词

melanoma metastatic melanoma BRAF V600 melanoma NRAS melanoma KIT melanoma PD-1 melanoma CTLA-4 melanoma immunotherapy melanoma uveal melanoma

Keyword guide

这些关键词怎么理解

术语	中文意思	对找临床试验有什么用
转移性黑色素瘤 / Metastatic melanoma	黑色素瘤已经扩散到远处器官或组织。	很多系统治疗或免疫治疗试验会限定 metastatic 患者。
BRAF V600	黑色素瘤中重要的可检测突变类型之一。	可以找 BRAF/MEK 抑制剂、联合免疫治疗相关试验。
NRAS mutation	另一类黑色素瘤相关突变。	可以找 MEK、免疫联合或 RAS pathway 相关试验。
KIT mutation	部分黏膜型或肢端型黑色素瘤可能出现 KIT 改变。	可以找 KIT inhibitor 或特定亚型试验。
PD-1 / CTLA-4	免疫检查点治疗相关靶点。	黑色素瘤海外试验常见免疫治疗、联合治疗或耐药后治疗方向。
Uveal melanoma	葡萄膜黑色素瘤，和皮肤黑色素瘤不同。	需要单独搜索 uveal melanoma，试验方向不同。

Recruitment status

常见招募状态

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

Before contact

联系前准备资料

病理诊断报告
影像报告：CT / MRI / PET-CT
既往治疗记录
用药历史
基因检测报告
最近血液检查结果
出院小结
主治医生英文病情摘要，如果有
护照和签证情况，如果考虑出国

Filters

搜索时重点关注

Recruiting / Not yet recruiting
Location
Age
Phase
Inclusion Criteria
Exclusion Criteria
Prior treatments
Biomarker / mutation requirements
ECOG performance status
是否接受 international patients
是否需要长期停留在试验所在地
费用、保险、翻译、住宿和陪护安排

Ask your doctor

可以带去问医生的问题

我的病理类型是否符合这个试验？
我之前用过的药会不会影响入组？
我是否需要做基因检测？
这个试验是几期？主要目的是什么？
参加试验会不会影响当前治疗？
如果去国外参加，风险和成本大概有哪些？
研究团队是否接受海外患者？

下一步提示

请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。